Establishing a COVID-19 pandemic severity assessment surveillance system in Ireland

Lisa Domegan1,2 | Patricia Garvey1 | Maeve McEnery1 | Rachel Fiegenbaum1 | Elaine Brabazon3 | Keith Ian Quintyne3 | Lois O'Connor1 | John Cuddihy1 | Joan O'Donnell1

1Health Service Executive, Health Protection Surveillance Centre, Dublin, Ireland
2European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
3Department of Public Health, Health Service Executive North-East, Navan, Ireland

Correspondence
Lisa Domegan, Health Service Executive, Health Protection Surveillance Centre, Dublin, Ireland.
Email: lisa.domegan@hse.ie

Abstract
We developed a COVID-19 pandemic severity assessment (PSA) monitoring system in Ireland, in order to inform and improve public health preparedness, response and recovery. The system based on the World Health Organization (WHO) Pandemic Influenza Severity Assessment (PISA) project included a panel of surveillance parameters for the following indicators: transmissibility, impact and disease severity. Age-specific thresholds were established for each parameter and data visualised using heat maps. The findings from the first pandemic wave in Ireland have shown that the WHO PISA system can be adapted for COVID-19, providing a standardised tool for early warning and monitoring pandemic severity.

KEYWORDS
COVID-19, pandemic, pandemic severity assessment, surveillance

1 | INTRODUCTION

Pandemic severity assessments (PSAs) provide information to determine the timing, scale and intensity of pandemics and to support decisions on the urgency of pandemic response actions and on implementing and lifting control measures.1–3 In the absence of a national surveillance system for assessing the severity of pandemics in Ireland, we adapted the WHO Pandemic Influenza Severity Assessment (PISA)2 methodology for COVID-19. The WHO PISA project defined pandemic severity in terms of three indicators: transmissibility, seriousness of disease and impact. Transmissibility reflects the ease of transmission of viruses between individuals and communities. The seriousness of disease indicator describes the extent to which individual people get sick when infected. The impact indicator describes how the pandemic affects society (e.g., excess mortality) and the health-care sector (e.g., hospitalisations).2 Following the declaration of the COVID-19 pandemic on the 11 March 2020,4 we aimed to develop and implement a PSA monitoring system in Ireland, in order to inform public health preparedness, response and recovery measures, and to assist in improving the response to future waves of COVID-19.

2 | METHODS

A series of surveillance parameters for each indicator was identified and analysed by age group (0–14, 15–64 and ≥65 years), overall and week (Table 1). Threshold levels for each parameter were developed (by age group, overall and week) and applied to datasets from the first COVID-19 wave (March–June 2020) in Ireland.

Age-specific statistical thresholds for transmissibility and impact parameters (baseline to extraordinary) were calculated using the Moving Epidemic Method based on historical data (previous 5 years).5 An upper ‘super-extraordinary’ threshold level was...
established to compare peak pandemic activity of each pandemic wave. Threshold levels used to measure excess mortality (Z scores) were those used by the European Mortality Monitoring Project, EuroMOMO.6 Historical data from syndromic surveillance datasets such as general practice (GP) out-of-hours (OOHs) calls and sentinel GP influenza-like illness (ILI) consultations were available for threshold calculation. In the absence of historical COVID-19 data, historical influenza datasets were used as a proxy to calculate COVID-19 thresholds. The thresholds for the seriousness of disease indicator were calculated based on means and standard deviations using cumulative historical influenza data for the previous five seasons on confirmed cases, hospitalisations and intensive care/critical care unit (ICU) admissions and deaths. Changes to national recommendations, case definitions, policy and testing strategies were documented to assist with data interpretation.

| Indicators | Parameters | Type of data | Date used for analysis | Historic data used for thresholds |
|------------|------------|--------------|------------------------|----------------------------------|
| Transmissibility | Sentinel GP influenza-like illness rate/100 000 population | Syndromic/clinical | GP phone consultation date | Sentinel GP ILI consultation data |
| % GP OOHs flu calls (of total calls) | | Syndromic | Date of call to GP OOHs service | GP OOHs flu calls data |
| % GP OOHs cough calls (of total calls) | | | | GP OOHs cough calls data |
| COVID-19 outbreaks (excluding family outbreaks)—number | Outbreak surveillance data | | Date of outbreak notification | Influenza outbreak notifications |
| COVID-19 nursing home outbreaks—number | Outbreak surveillance data | | Date of outbreak notification | |
| SARS-CoV-2% positivity—NVRL-UCD | Laboratory testing data | Date of test | Influenza % positivity—NVRL-UCD |
| COVID-19 confirmed cases—number | Notifications—lab confirmed only | Date of notification | Influenza confirmed case notifications |
| COVID-19 incidence per 100 000 population | | | | |

**Impact**

| Indicators | Parameters | Type of data | Date used for analysis | Historic data used for thresholds |
|------------|------------|--------------|------------------------|----------------------------------|
| COVID-19 hospitalised confirmed cases—number | Notifications—lab confirmed only | Date of notification | Confirmed influenza hospitalised notified cases |
| COVID-19 hospitalised confirmed cases—per 100 000 population | | | | |
| COVID-19 confirmed ICU cases—number | Notifications—lab confirmed only | Date of notification | Confirmed influenza ICU notified cases |
| COVID-19 confirmed ICU cases—per 100 000 population | | | | |
| COVID-19 confirmed cases that died—number | Notifications—lab confirmed only | Date of notification | Confirmed influenza case notifications that died |
| COVID-19 mortality rate per 1 000 000 population | | | | |
| Excess mortality—All cause (Z scores) | All cause death registrations | Date of death | All cause death registrations |

**Seriousness**

| Indicators | Parameters | Type of data | Date used for analysis | Historic data used for thresholds |
|------------|------------|--------------|------------------------|----------------------------------|
| COVID-19 cumulative % cases hospitalised | Notifications—lab confirmed only | Cumulative by week of notification | % confirmed influenza cases hospitalised |
| COVID-19 cumulative % hospitalised cases admitted to ICU | | | % confirmed influenza hospitalised cases admitted to ICU |
| COVID-19 case fatality ratio (CFR)—all Cases | Notifications—lab confirmed only | Cumulative by week of notification | Influenza CFR—all cases (lab confirmed only) |
| COVID-19 CFR—hospitalised cases | | | | |
| COVID-19 CFR—ICU cases | | | | |

---

*The numerator is the total number of SARS-CoV-2 positive tests, and the denominator is the total number of tests for SARS-CoV-2 tested in the National Virus Reference Laboratory, University College Dublin (NVRL-UCD). Abbreviations: ICU, intensive care/critical care unit; ILI, influenza-like illness; GP, general practice; OOH, out-of-hour; PSA, pandemic severity assessment.*
RESULTS

3.1 Transmissibility

During the first COVID-19 pandemic wave (March–June 2020) in Ireland, GP OOHs cough calls first exceeded baseline levels during Week 10 2020 (week ending 08 March 2020) (Figure 1). COVID-19 incidence per 100 000 population exceeded extraordinary levels for five consecutive weeks (30 March 2020 to 03 May 2020). The number of notified COVID-19 outbreaks (excluding family outbreaks) exceeded baseline levels for 16 consecutive weeks and were at moderate levels by the end of June 2020, when restrictions were gradually eased over the 2020 summer.

Parameters used to monitor incidence in those aged less than 15 years old were below baseline levels or at low levels for most of the first COVID-19 pandemic wave, with the exception of the proportion of GP OOHs cough calls which exceeded extraordinary levels for 2 weeks (09 March 2020 to 22 March 2020). The sentinel GP ILI consultation rate for the 0- to 14-year age group increased considerably between Weeks 11 and 12 2020, followed by a decrease below baseline within 2 weeks of school closures (schools in Ireland closed on 12 March 2020 and remained closed for the academic year).

For the 15- to 64-year age group, COVID-19 incidence exceeded extraordinary levels for eight consecutive weeks, peaking at 175.7 per 100 000 population during Week 16 2020 (week ending 19 April 2020) and still remained above baseline levels at the end of the first COVID-19 pandemic wave. COVID-19 age specific incidence was highest for those aged 65 years and older, peaking at 242.3 per 100 000 population during Week 17 2020 (week ending 26 April 2020).
The impact of the COVID-19 pandemic during the first wave varied by age group. Levels were primarily below baseline for those aged 0–14 years and exceeded extraordinary levels for the 15- to 64-year age group and for those aged 65 years and older (Figure 2). The impact on those aged 65 years and older was particularly severe, with mortality rates at very high levels for a period of nine consecutive weeks (exceeding extraordinary levels for seven consecutive weeks), peaking at 497 per 1,000,000 population during the week ending 19 April 2020. Excess all-cause mortality was observed for seven consecutive weeks (late March to early May 2020) with the highest Z scores for excess deaths ever reported in Ireland. All impact parameters (hospitalisation and ICU admission rates) were below baseline for all ages by the end of the first pandemic wave, with the exception of the mortality rate which remained at low levels.

### 3.2 | Impact

By the end of the first COVID-19 wave in Ireland, the cumulative proportion of hospitalised cases admitted to ICU was at extraordinary levels in those aged 15–64 years (19.0%) and for all ages (13.1%) and high for those aged 65 years and older (8.9%). Only five paediatric COVID-19 cases were admitted to ICU during the first COVID-19 pandemic wave.

The case fatality ratio (CFR) for all cases was at extraordinary levels for those aged 65 years and older (21.7%) and for all ages (6.0%) and at low levels for those aged 15–64 years (0.5%). There were no COVID-19 deaths notified in the 0–to 14-year age group in Ireland. The CFR in hospitalised cases was at extraordinary levels for those aged 65 years and older (34.7%) and for all ages (21.4%) and at high levels for those aged 15–64 years (5.9%).

---

| Week Number | March | April | May | June |
|-------------|-------|-------|-----|------|
| 10          | 0.3   | 0.2   | 0.3 | 0.2  |
| 11          | 0.2   | 0.2   | 0.2 | 0.2  |
| 12          | 0.2   | 0.3   | 0.3 | 0.3  |
| 13          | 0.3   | 0.3   | 0.3 | 0.3  |
| 14          | 0.3   | 0.3   | 0.3 | 0.3  |
| 15          | 0.3   | 0.3   | 0.3 | 0.3  |
| 16          | 0.3   | 0.3   | 0.3 | 0.3  |
| 17          | 0.3   | 0.3   | 0.3 | 0.3  |
| 18          | 0.3   | 0.3   | 0.3 | 0.3  |
| 19          | 0.3   | 0.3   | 0.3 | 0.3  |
| 20          | 0.3   | 0.3   | 0.3 | 0.3  |
| 21          | 0.3   | 0.3   | 0.3 | 0.3  |
| 22          | 0.3   | 0.3   | 0.3 | 0.3  |
| 23          | 0.3   | 0.3   | 0.3 | 0.3  |
| 24          | 0.3   | 0.3   | 0.3 | 0.3  |
| 25          | 0.3   | 0.3   | 0.3 | 0.3  |
| 26          | 0.3   | 0.3   | 0.3 | 0.3  |
A PSA surveillance system for COVID-19 was established for Ireland. The panel of parameters selected enabled assessment of all indicators and age-group differences for transmissibility, severity and impact and was based on an adapted WHO PISA model. Two parameters proved very timely and appeared sensitive for the early detection of COVID-19, namely, data on GP OOHs cough calls and COVID-19 ICU admission rates. GP syndromic parameters were sensitive and timely for the early detection of changing trends in paediatric age groups.

The PSA surveillance system is designed to be flexible. Parameters included may change over time as more suitable parameters are identified, such as sentinel GP SARS-CoV-2 positivity and CFR in nursing homes. Homologous data for threshold calculation were used for some parameters (e.g., GP ILI consultations) and not for COVID-19 specific parameters. The lack of historical COVID-19 data for the development of thresholds is a limitation. As Ireland moves through successive COVID-19 waves, one consideration is to use data from earlier waves to develop thresholds. WHO recommends inclusion of confidence levels when reporting PISA parameters, which would enhance data interpretation, in particular with limitations of available historical data for threshold calculation. There was a lower level of confidence in data reported during the initial weeks of the pandemic, due to the rapid evolution of the situation and frequent changes to testing capacity, criteria for testing and case definitions.

Our study provided an epidemiological description and assessment of the severity of the first COVID-19 pandemic wave in Ireland. The heat maps were easily understood, concurred with the epidemiological situation and were reported to the National Public Health Emergency team. This PSA system will be used going forward in conjunction with enhanced surveillance data to monitor COVID-19 activity in Ireland. We believe this is a useful surveillance tool to inform and guide national decisions and recommendations on public health interventions and for guiding control measures in Ireland as we move through pandemic waves. We have shown that the WHO PISA system can be adapted for COVID-19 in Ireland (and possibly other pathogens with pandemic potential), providing a standardised tool to monitor pandemic severity and for early warning for current and future pandemic waves. Syndromic surveillance data are effective and timely when assessing pandemic severity, particularly when testing capacity may change and for monitoring novel respiratory pathogens (with no existing microbiological tests).

We recommend that PSAs, using this PSA system, be conducted regularly in Ireland as the pandemic progresses. We also recommend that other transmissibility measures such as reproductive numbers are considered for integration into the WHO PISA framework in the future. Current and future applications of this PSA system in Ireland include monitoring the impact of the COVID-19 vaccination programme, the changing epidemiology due to SARS-CoV-2 variants of concern and monitoring both SARS-CoV-2 and influenza each winter.

**ACKNOWLEDGEMENTS**

Sincere thanks are extended to all those who are participating in the collection, testing, reporting and analysing of COVID-19 data in Ireland. This includes all staff at the Health Protection Surveillance Centre (in particular the COVID-19 epidemiological and CIDR teams), Departments of Public Health, Irish sentinel GP network, National Virus Reference Laboratory, hospital microbiology/other laboratories, the HSE COVID-19 Contact Management Programme, COVID-19 community operations, Department of Health, hospital/ICU staff, notifying clinicians, laboratory staff, public health doctors, nurses, surveillance scientists/epidemiologists, microbiologists and administrative staff. Thanks are also extended to all EPIET supervisors and coordinators for their advice during this project. No funds, grants or other support was received.

**AUTHOR CONTRIBUTIONS**

Lisa Domegan: Investigation; conceptualization; methodology; formal analysis; writing-review and editing. Patricia Garvey: Supervision; writing-review and editing. Maeve McEnery: Data curation; validation; writing-review and editing. Rachel Fiegenbaum: Data curation; validation; writing-review and editing. Elaine Brabazon: Data curation; writing-review and editing. Keith Ian Quintyne: Data curation; writing-review and editing. Lois O’Connor: Supervision; writing-review and editing. John Cuddihy: Supervision; writing-review and editing. Joan O’Donnell: Supervision; writing-review and editing.

**CONFLICT OF INTEREST**

The authors have no conflicts of interest to declare that are relevant to the content of this article.

**ETHICS APPROVAL**

Not required; aggregated anonymised routine surveillance data were used in this study.

**CONSENT TO PARTICIPATE**

Not required; aggregated anonymised routine surveillance data were used in this study.

**CONSENT FOR PUBLICATION**

Not applicable.

**CODE AVAILABILITY**

Not applicable.

**PEER REVIEW**

The peer review history for this article is available at https://publons.com/publon/10.1111/irv.12890.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author, upon reasonable request.
REFERENCES
1. Reed C, Biggerstaff M, Finelli L, et al. Novel framework for assessing epidemiologic effects of influenza epidemics and pandemics. Emerg Infect Dis. 2013;19(1):85-91. https://doi.org/10.3201/eid1901.120124
2. World Health Organization. (2017). Pandemic Influenza Severity Assessment (PISA): a WHO guide to assess the severity of influenza in seasonal epidemics and pandemics. https://apps.who.int/iris/handle/10665/259392
3. World Health Organization. (2020). Considerations for implementing and adjusting public health and social measures in the context of COVID-19. https://www.who.int/publications/i/item/considerations-in-adjusting-public-health-and-social-measures-in-the-context-of-covid-19-interim-guidance
4. World Health Organization. (2020). Report of the Review Committee on the Functioning of the International Health Regulations (2005) during the COVID-19 response. https://cdn.who.int/media/docs/default-source/documents/emergencies/a74_9add1-en.pdf?sfvrsn=d5d22fd6_1&download=true
5. Vega T, Lozano JE, Meerhoff T, et al. Influenza surveillance in Europe: comparing intensity levels calculated using the moving epidemic method. Influenza Other Respi Viruses. 2015;9(5):234-246. https://doi.org/10.1111/irv.12330
6. Mazick A, Gergonne B, Nielsen J, et al. Excess mortality among the elderly in 12 European countries, February and March 2012. Euro Surveill. 2012;17(14):20138. https://doi.org/10.2807/ese.17.14.20138-en
7. ECDC Public Health Emergency Team, Danis K, Fonteneau L, et al. High impact of COVID-19 in long-term care facilities, suggestion for monitoring in the EU/EEA, May 2020. Euro Surveill. 2020;25(22):2000956. https://doi.org/10.2807/1560-7917.ES.2020.25.22.2000956
8. European Centre for Disease Prevention and Control. Increase in fatal cases of COVID-19 among long-term care facility residents in the EU/EEA and the UK. 19 November 2020. ECDC: Stockholm; 2020. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-increase-fatal-cases-covid-19-among-long-term-care-facility
9. HPSC. COVID-19 Surveillance Reports, 2020–2021. https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/
10. Ferenczi A, Mereckiene J, O’Connor L, O’Donnell J. Epidemiological report of COVID-19 cases in Ireland, 2 March 2020 – 15 August 2020. Epi-Insight. September 2020;21(4). https://www.hpsc.ie/epi-insight/volume212020/
11. National COVID-19 Vaccination Programme Strategy. 2020. https://www.gov.ie/en/publication/bf337-covid-19-vaccination-strategy-and-implementation-plan/
12. European Centre for Disease Prevention and Control. Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK – 2 December 2020. ECDC: Stockholm; 2020. https://www.ecdc.europa.eu/en/publications-data/overview-current-eu-eea-uk-plans-covid-19-vaccines
13. European Centre for Disease Prevention and Control. Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA, first update – 21 January 2021. ECDC: Stockholm; 2021. https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update

How to cite this article: Domegan L, Garvey P, McEnery M, et al. Establishing a COVID-19 pandemic severity assessment surveillance system in Ireland. Influenza Other Respi Viruses. 2022;16(1):172-177. https://doi.org/10.1111/irv.12890